ieso awarded multi-year national contract with NHS Scotland
We are delighted to announce that ieso were recently awarded a renewed multi-year national contract with NHS Scotland starting from 1st December 2023 to continue delivering typed therapy to all 14 Scottish health boards.
Our evidence-based digitally-enabled therapy is available to people aged 16+ in both rural and urban areas all across Scotland with shorter waits to treatment compared to traditional face-to-face therapy. We strive to make therapy more accessible through our out-of-hours appointment slots and our targeted campaigns that highlight the service and access to therapy in the Scottish Isles where patients are currently able to self-refer.
About the continued partnership between ieso and NHS Scotland, Chris Wright, National Advisor for Digital Mental Health at The Scottish Government said: “ieso delivers a quality service that is safe, effective and flexible and is proven accessible in some of the most remote areas of Scotland. ieso are a valued partner in Scotland and we are delighted that this partnership will continue to develop and grow in the next couple of years where it will play a significant role as we expand our digital therapies capability across mental health services.”.
Arif Hussain, ieso Customer Success Manager added: “Together with NHS Scotland, ieso are committed to expanding the reach of online typed CBT, empowering individuals facing common mental health problems like anxiety or depression to access care from mental health professionals conveniently from home, at a time that suits them. This multi-year commitment not only enhances the well-being of the Scottish population but also aligns seamlessly with the Scottish Government's Digital Health and Care Strategy.”
Learn more about how ieso partners with the NHS here: https://www.iesogroup.com/nhs
For UK Time to Talk Day, the ieso clinical offer their advice on how to start a conversation about mental health
In this team spotlight interview, we spoke to Dr Alyssa Dietz about her role as Head of US Clinical Strategy.